Introduction
Recent studies have identified cell surface antigens on murine and human tumors of various histotypes that are potential targets for an immune response. These antigens, which are recognized by host T cells, derive from endogenously synthesized proteins that arise either through mutations during malignant transformation or through aberrant expression of genes normally silent in adult tissues. 1 However, these antigens are usually weak immunogens in spontaneously arising tumors.
In an effort to elicit an immune response against tumor antigens, various micro-organisms, especially Mycobacterium bovis bacillus Calmette-Guérin (BCG), have been used as immunoadjuvants in patients with different cancer types, but the results have been variable. 2 At present, patients with superficial bladder cancer are being treated with immunotherapy consisting of intravesical instillation of BCG. There is some evidence that a similar mechanism underlies the efficacy of BCG in tumor prevention and therapy 3 and in prophylaxis against tuberculosis. This efficacy appears to depend on whether a predominant Th1-or a Th2-type cytokine secretion pattern is induced. 2 In another approach to stimulating an immune response against tumors, different cytokine genes have been introduced into tumor cells. The secreted cytokines have been shown to induce a protective immune reaction against the tumor. 4 For example, administration of engineered tumor cells expressing interleukin-2 (IL-2), IL-4, interferon-gamma (IFN-␥) or granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to induce local and often systemic immunity, although elimination of pre-existing tumors was less frequently achieved. 5 However, in some cases, cytokine-engineered tumor cells reportedly display an increased metastatic potential. 6 Because the combination of poorly immunogenic and highly immunogenic determinants on a common carrier can augment the immune response toward the poorly antigenic determinants by stimulating immune recognition, 7 we asked whether the immune recognition of malignant cells might be enhanced by transducing tumor cells with a gene that encodes a mycobacterium protein, that should represent a danger signal, since it induces a strong T cell response. 8 If the expression of this gene leads to enhanced Th1 cell maturation, a T cell response might also be induced against the tumor cell antigens and eventually result in the selective destruction of tumor cells through a specific antitumor immune response. 2 In this study, we transduced the murine melanoma cell line B16-B78 with a Mycobacterium tuberculosis (strain H37Rv) gene encoding a 38-kDa protein (Ag38), 9 which is one of the most immunogenic of the Mycobacterium tuberculosis antigens. 10 Transduced cells were injected into mice and the immune response against parental B16-B78 melanoma cells was evaluated.
Results and discussion
Tumorigenicity of transduced melanoma cells A modified retroviral vector (pLTMSN) containing the leader and transmembrane portion of the human nerve growth factor receptor (NGFR) and the stop codon region of human IL-3 was constructed. The DNA encoding residues 24-372 of Mycobacterium tuberculosis Ag38 gene, excluding the leader peptide and the stop codon, was cloned in-frame to obtain the pLAg38TMSN vector ( Figure 1 ). This modified vector expresses the 38-kDa antigen on the cell surface, allowing detection and tagging of transduced cells by an anti-Ag38 monoclonal antibody (MAb), HBT12. 9 The supernatant of the producer cell lines was tested for viral titer and antigen expression by FACScan analysis with MAb HBT12 and used for infection of B16-B78 murine melanoma cells. 11 Transduced cells expressed the Mycobacterium tuberculosis Ag38 transcript and produced the bacterial protein as detected by RT-PCR ( Figure 2a ) and Western blot (Figure 2b ), respectively. Reactivity with MAb HBT12 revealed two bands in the total cell membrane extract at 47 kDa and 42 kDa, corresponding, respectively, to the unprocessed form, which contains both the leader and transmembrane sequences, and to the mature protein after cleavage of the leader sequence. The majority of transduced B16-B78 cells were positive for cell surface expression of the mycobacterial protein as determined by FACS analysis (Figure 2c ). Both wild-type and melanoma cells transduced with the vector lacking the Ag38 gene showed no detectable mycobacterial product by RT-PCR, Western blot or FACS analysis.
The tumorigenicity of the parental melanoma cell line and of the cells transduced with the 38-kDa gene was tested in C57BL/6 mice. All five mice injected subcutaneously (s.c.) with 2.5 × 10 5 B16-B78 cells developed tumors within 9-21 days (mean 13.8) and had a mean survival time of 36.6 days. Necroscopy revealed lung metastases in all of these mice. By contrast, three of five mice injected with 2.5 × 10 5 transduced melanoma cells developed tumors and these mice showed a delay in appearance of the tumor (mean 30.6 days) that resulted in an increase in survival time (mean 52.3 days); no metastases were observed in the lungs, liver, kidneys or peritoneal cavity. Two other 38-kDa-transduced clones, obtained in independent transductions, also showed no spontaneous metastasis (not shown), making it unlikely that the Ag38 gene was inserted into a gene involved in metastasis. However, the absence of spontaneous metastasis cannot be definitively attributed to the expression of Ag38 since B16 melanoma cells are reportedly heterogeneous with respect to metastatic potential.
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Ag38-transduced melanoma cells confer systemic immunity against parental melanoma cells In experiments to determine whether immunization with transduced melanoma cells protected mice against a subsequent challenge with parental cells (Figure 3 ), all of nine naive mice and eight of 10 mice immunized with wild-type melanoma cells developed tumors, whereas significant protection (P Ͻ 0.01) was observed in mice immunized with the transduced melanoma cells, since only two of 10 mice developed tumors. Moreover, in these mice, the onset of tumor development as well as the mortality were delayed in comparison with nonimmune and wild-type melanoma-immunized animals.
Since wild-type melanoma cells are highly tumorigenic and poorly immunogenic, these data suggest that the expression of the 38-kDa antigen in transduced cells elicits a strong immune response against the tumor. Endogenous expression of Ag38 appears to be essential for protection, since C57BL/6 mice immunized with the purified 38-kDa protein developed tumors at the same rate as non-immunized controls when challenged with wild-type melanoma cells (not shown).
Experimental metastases induced by i.v. inoculation with 5 × 10 5 wild-type melanoma cells were inhibited in mice immunized with irradiated Ag38-transduced cells as indicated by the absence or the low number of lung metastases at 4 weeks after challenge, as compared with control mice (Figure 4a) . Two experiments were performed using the same challenge protocol to evaluate the effect of immunization on survival time. In the first experiment (Figure 4b ), the six mice immunized with Ag38-transduced cells survived significantly longer than the six non-immunized control mice (P = 0.0005), which all developed lung metastases and died within 31 days of tumor inoculation. Two of the six immunized mice were still alive at the end of the observation period (90 days). In the second experiment, a significant increase in survival time (P = 0.0001) was observed in the eight immunized mice versus the eight control mice, and two animals were still alive after 150 days. These data indicate that vaccination with murine melanoma cells transduced with the 38-kDa Mycobacterium gene induces a significant inhibition of lung metastases of i.v.-injected parental tumors, leading to prolonged survival.
Th1-and Th2-type cytokine secretion pattern Based on increasing evidence that suggests the importance of the Th1-type response in the control of tumor growth, we evaluated the Th1-and Th2-types of reactions in mice injected in the footpad with: (1) irradiated wildtype melanoma cells; (2) irradiated transduced cells; and (3) irradiated wild-type melanoma cells plus the 38-kDa
Figure 2 Expression of Ag38 in transduced cells. (a) Detection of Ag38 mRNA by RT-PCR of total RNA from: B16-B78 wild-type melanoma cells (lane 2); B16-B78 cells transduced with pLTMSN vector (lane 3); B16-B78 cells transduced with pLAg38TMSN vector (lane 4); and pLAg38TMSN vector (lane 5). Lane 1, molecular weight marker (1 kb ladder). (b) Detection of Ag38 protein by Western blot analysis of membrane proteins extracted from: B16-B78 wild-type melanoma cells (lane 2); B16-B78 cells transduced with pLTMSN vector (lane 3); and B16-B78 cells transduced with pLAg38TMSN vector (lane 4). Lane 1, bacterial recombinant Ag38 protein. (c) Detection of Ag38 protein by FACScan analysis on the surface of B16-B78 cells transduced with pLTMSN vector (top) and B16-B78 cells transduced with pLAg38TMSN vector (bottom). Open areas indicate cells stained with secondary antibody alone.
purified protein. As reported in Table 1 , analysis of cytokine levels in the culture supernatants of lymphocytes obtained from ipsilateral popliteal lymph nodes revealed an increase in IFN-␥ levels in mice injected with transduced cells compared with mice injected with irradiated wild-type melanoma cells and with mice injected with irradiated wild-type melanoma cells plus the 38-kDa purified protein. In contrast, secreted IL-4 levels were higher in mice treated with wild-type B16 plus purified 38-kDa protein than in mice injected with transduced cells. Th1 switch was further confirmed by the finding that IL-2 was detectable only in the supernatant of lymphocytes from animals injected with transduced cells (data not shown). The induction of a preferential Th1 cytokine secretion pattern by endogenously expressed mycobacterial antigen is consistent with studies by Huygen et al 13 and Zhu et al, 14 who showed that vaccinations with plasmid DNA constructs encoding the 85T or 38-kDa Mycobacterium tuberculosis antigens are a powerful approach to generating a specific helper response with a Th1-like phenotype.
As previously reported, 15 the B78 variant of melanoma B16 expressed undetectable levels of major histocompatibility complex (MHC) class I antigens in vitro, even after exposure to IFN-␥ (not shown). Low expression of class I antigens frequently characterizes advanced tumors and metastases in humans. 16 Indeed, down-regulation of MHC class I expression is an important mechanism by which tumors may evade T cell-mediated immune responses. The expression of the 38-kDa protein on the B16-B78 melanoma cell surface might stimulate MHCnonrestricted cells, such as ␥/␦ T cells, which in turn influence the initial activation of the Th1 cell subset.
Irrespective of MHC context, a recent report suggests that immunologic intervention with molecules that selectively activate Th1 responses may be effective in activating NK cells, cytotoxic T lymphocytes, and tumoricidal macrophages, thus increasing the killing of tumor cells. 17 Enhancement of the immune response against tumor antigens has been achieved by transducing tumor cells with two different genes encoding heat-shock protein (HSP) 65 from Mycobacterium leprae 18 and Mycobacterium bovis. 19 HSPs are molecular chaperones that mediate the assembly and folding of other proteins. 20 HSPs are also associated in vivo with the entire repertoire of peptides generated within the cell, and these noncovalent HSPpeptide complexes are particularly immunogenic. 21 In this article, we have shown that the expression of a Mycobacterium tuberculosis protein lacking chaperone activity 22 can enhance the immunogenicity of weakly antigenic tumor cells defective in costimulatory molecules and not expressing detectable levels of MHC antigens.
It remains to be determined whether all tumors express antigens that can be rendered immunogenic by genetic manipulation or whether these molecules are restricted to some neoplasms. Transductions in other experimental tumors are required to address this issue. Further studies are also required to ascertain the precise mechanisms involved as well as the optimal vaccination procedures. Nevertheless, this transduction approach may offer a promising immunotherapeutic strategy for the treatment of cancer.
Materials and methods

Retroviral construct
A SacII-PvuII fragment containing the first 843 bp of the nerve growth factor receptor (NGFR) lacking the intracellular domain was cloned into pGEM 5Zf+ (Promega, Madison, WI, USA); the extracellular portion of the NGFR was excised with StuI and AvaI and replaced inframe with a synthetic polynucleotide sequence containing three unique cloning sites (NotI, ClaI and EcoRV) (designated pLTM). At the 3′-end, the last 28 bp of the human IL-3 sequence, containing the stop codon, were joined in-frame by replacement of the NcoI-NheI IL-3 fragment with the SacII-SpeI fragment of pLTM in the pBBG14 vector (British Biotechnology, Oxon, UK). The entire construct was excised from the plasmid (HindIIIBamHI) and ligated into the HpaI-BamHI sites of the retroviral vector pLXSN (courtesy of Dr D Miller, Fred Hutchinson Center, Seattle, WA, USA). The entire vector, designated pLTMSN, was sequenced using the Sanger method 
(a) Lung metastases from mice immunized with irradiated transduced B16-B78 melanoma cells (upper) and from non-immunized mice (bottom). (b) Survival of immunized mice (dashed line) and of non-immunized mice (solid line).
Table 1 Secretion of IL-4 and IFN-␥ in supernatants from lymphocytes of melanoma-injected mice
Injected antigen
Cytokine production (pg/ml)
a Data refer to a representative experiment performed in triplicate and are expressed as the mean ± s.d. obtained by subtracting the cytokine levels in the supernatant of lymphocytes cultured in the absence of anti-CD3 antibody. IL-4:IFN-␥ ratio between: B16 transduced to B16 P = 0.0013; B16 transduced to B16 + Ag38 P = 0.0109 (unpaired t test).
(Sequenase Version 2; USB Amersham Life Science, Cleveland, OH, USA). DNA encoding residues 24-372 of Mycobacterium tuberculosis Ag38 was obtained by PCR using plasmid pMS9-2 9 as a template and two primers modified to include NotI and ClaI sites at the 5′ and 3′ ends, respectively. The sense primer was 5′-GCGGCCGCTGGCTCG AAACCACCGAGCGGTTCGCCTGAA-3′, corresponding to nucleotides 215-246 of the Ag38 gene, and the antisense primer was 5′-GCGGTGGTGAAGTTGTCTGACGCGTTG ATCGCATC GATT-3′, corresponding to nucleotides 1235-1267. PCR was performed for 30 cycles of 1 min at 94°C, 1 min at 55°C and 2 min at 72°C. The PCR product was digested with NotI and ClaI restriction enzymes and ligated in-frame in the corresponding sites of the pLTMSN retroviral vector to obtain the pLAg38TMSN vector (Figure 1) . Retroviral particles were obtained by infection techniques as described, 23 using the ampho-ecotropic packaging cell lines gp+AM12 and gp+E86. 24, 25 G418-resistant individual colonies of producer cells were screened for cell surface Ag38 expression by FACScan analysis using antiAg38 MAb HBT12. 9 Virus produced by the best packaging cell line, in terms of viral titer and antigen expression, were used to infect murine melanoma cells.
Mycobacterium gene transduction and expression in cells B16-B78 murine melanoma cells 11 (6 × 10 5 ) were cultured for 2 h with 5 ml of undiluted viral supernatant from the packaging cell line and 8 g/ml of polybrene; fresh medium was then added to dilute the supernatant (1 : 2) for the following 24 h. To improve infection efficiency, the same infection cycle was repeated five times. Individual colonies as well as bulk cultures of G418-selected (1 mg/ml) melanoma cells were tested for 38-kDa antigen gene expression by RT-PCR, FACScan analysis and Western blotting.
G418-resistant colonies recovered from B16-B78 melanoma cells transfected with the empty vector were used as controls.
For RT-PCR, total RNA was obtained from 1 × 10 7 cells (Rneasy Handbook; Qiagen, Hilden, Germany); 1 g of the RNA was reverse-transcribed (GeneAmp RNA PCR Kit; Perkin-Elmer Cetus, Norwalk, CT, USA) and the cDNA was amplified by PCR utilizing the same 5′ primer used for cloning and a 3′ primer (5′-TGATCG-CCCAGTGCAGAAAT-3′) corresponding to nucleotides 1265-1284. Thirty cycles of amplification (1 min at 94°C, 1 min at 55°C and 2 min at 72°C) were performed and the reaction product (950 bp) was electrophoresed and stained with ethidium bromide.
Flow cytometry was used to detect cell surface antigen. Briefly, cells were incubated for 30 min at 4°C with 10 g/ml of the anti-Ag38 purified MAb HBT12, washed and incubated for an additional 30 min at 4°C with goat antimouse IgG+IgM(H+L) FITC-conjugated secondary antibody (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA). After washing, cells were analyzed by FACScan (Becton Dickinson, Mountain View, CA, USA).
For Western blot analysis, membrane protein extract was obtained according to Landowski et al 26 with minor modifications: 1.5 × 10 8 cells were lysed in ice-cold 25 mm Tris/0.3 m sucrose (pH 7.4) buffer, including protease inhibitor, by sonication with 5 × 5 s bursts on ice, followed by centrifugation at 500 g for 10 min at 4°C. This step was repeated three times and the supernatant was collected. The membrane fraction was recovered by centrifugation of the supernatant at 143 000 g for 90 min at 4°C. The pellet was resuspended and rotated end-over-end for 12-16 h at 4°C in 50 mm Tris/150 mm NaCl, pH 7.4, buffer containing 1% NP40 detergent and protease inhibitor. Insoluble material was pelleted by centrifugation at 200 000 g for 60 min and the supernatant was electrophoresed on a 15% reducing SDS-PAGE gel. Proteins were detected using MAb HBT12 as primary antibody and visualized with peroxidase-coupled secondary antibody using the ECL detection system (Amersham).
In vivo experiments C57BL/6 female mice, 6 to 8 weeks old, were purchased from Charles River (Calco, Italy). All mice were handled and treated in accordance with institutional guidelines.
Tumorigenicity In experiments to test a vaccination protocol against experimental lung metastases, mice were immunized with irradiated cells as described above followed by i.v. inoculation of 5 × 10 5 viable parental melanoma cells. Control mice received only the i.v. inoculation. Mice were killed 4 weeks later to determine the number of lung metastases. The same experimental protocol was used to evaluate the survival time in two experiments performed with six and eight animals per group, respectively. Differences between groups were analyzed using the log rank test.
In experiments to evaluate the patterns of cytokine release by T cells, mice (six per group) were immunized s.c. into the right hind footpad with 5 × 10 6 untransduced or transduced irradiated cells, or with 3 g Ag38 purified protein mixed with the untransduced irradiated cells, in 50 l of saline. Five days later, mice were killed and popliteal lymph nodes were aseptically removed. Pools for each group were made, each containing the nodes of two or three animals. Lymphocytes were mechanically dissociated and cultured (2 × 10 5 cells per well) in 96-well flatbottom plates precoated or not with 1 g/well of anti-CD3 MAb at 37°C for 18 h. Cytokine-containing supernatant was collected and tested for IFN-␥ and IL-4 production by ELISA commercial kits (Genzyme, Cambridge, MA, USA). Unpaired t test was used to evaluate the significance of differences for the IL-4 : IFN-␥ ratio between groups.
